Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:53:25.913Z.
Calculation as of: 2026-10-06T18:53:25.913Z.
Quote observation: 2026-10-06T18:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5b78614721c2e7423c3fee294265919eb0ef2e62d2038ec7ce10feded39bb20b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Tenaya Therapeutics, Inc.
Market Cap
$120.28M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | $120.28M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.93M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.12M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| BGM Group Ltd. (BGM)vs › | $118.06M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.54M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.06M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
